Status Awaiting development
Decision None selected
Process TAG
ID number 4050


Key events during the development of the guidance:

Date Update
27 May 2022 For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes

For further information on our processes and methods, please see our CHTE processes and methods manual